Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Alberta

$27,000.00

Defining the impacts of the plant-derived prebiotic fibre FOS used in infant formulas in place of human milk oligosaccharides in infants on antibiotics whose gut microbiota and fibre fermentation are altered

FY 2025-26

Summary
Dietary fibres are not digested in the human gut, instead they are fermented by gut microbes, producing typically healthy effects. Altered gut microbiome and reduced fibre fermentation are common in autoimmune diseases, however the impacts of unfermented fibres on the gut and overall health remains unclear. My MSc lab previously showed that specific types of dietary fibres (e.g., ß-fructan fibres) can cause inflammation and gut damage in disease states that display altered microbiome and reduced fermentation. Altered microbiome and diet are linked to early life risk of autoimmune diseases. Thus, I question whether antibiotic-driven changes to the gut microbiome in early life may sensitize infants to the ß-fructan oligosaccharide (FOS) that is added to infant formulas. FOS is derived from plants and is not found naturally in human breast milk; it is added in attempts to replicate the prebiotic properties of human milk oligosaccharides (HMOs) found in breast milk. I aim to examine the effects of FOS versus synthetic and breast-milk derived HMOs in infants taking antibiotics, where the gut microbiome is compromised. Based on my lab’s prior findings, I hypothesize that infants taking antibiotics will (1) have a gut microbiome that is less capable of fermenting FOS than non-antibiotic control microbiota samples, and (2) display inflammation and damage in response to unfermented FOS in colonic biopsies cultured ex vivo. My MSc research project will explore the microbial and host mechanisms underlying FOS and HMO impacts in the gut of infants with healthy versus altered gut microbiome. These findings may be used to investigate guidelines for infant formula selection (FOS-based vs synthetic HMOs) which may aid in reducing the risk of gastrointestinal conditions in the future.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
576681
Name
Rey-Dubois Cameron
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining the impacts of the plant-derived prebiotic fibre FOS used in infant formulas in place of human milk oligosaccharides in infants on antibiotics whose gut microbiota and fibre fermentation are altered
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Crohn'S Disease; Development; Dietary Fibre; Dysbiosis, Nutrition; Inflammatory Bowel Diseases; Inflammatory Pathways; Microbiome; Ss-Fructan; Ulcerative Colitis
Abstract
Dietary fibres are not digested in the human gut, instead they are fermented by gut microbes, producing typically healthy effects. Altered gut microbiome and reduced fibre fermentation are common in autoimmune diseases, however the impacts of unfermented fibres on the gut and overall health remains unclear. My MSc lab previously showed that specific types of dietary fibres (e.g., ß-fructan fibres) can cause inflammation and gut damage in disease states that display altered microbiome and reduced fermentation. Altered microbiome and diet are linked to early life risk of autoimmune diseases. Thus, I question whether antibiotic-driven changes to the gut microbiome in early life may sensitize infants to the ß-fructan oligosaccharide (FOS) that is added to infant formulas. FOS is derived from plants and is not found naturally in human breast milk; it is added in attempts to replicate the prebiotic properties of human milk oligosaccharides (HMOs) found in breast milk. I aim to examine the effects of FOS versus synthetic and breast-milk derived HMOs in infants taking antibiotics, where the gut microbiome is compromised. Based on my lab’s prior findings, I hypothesize that infants taking antibiotics will (1) have a gut microbiome that is less capable of fermenting FOS than non-antibiotic control microbiota samples, and (2) display inflammation and damage in response to unfermented FOS in colonic biopsies cultured ex vivo. My MSc research project will explore the microbial and host mechanisms underlying FOS and HMO impacts in the gut of infants with healthy versus altered gut microbiome. These findings may be used to investigate guidelines for infant formula selection (FOS-based vs synthetic HMOs) which may aid in reducing the risk of gastrointestinal conditions in the future.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rey-Dubois, Cameron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~